Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

Enveda Biosciences has raised $311 million in a funding round that brings the company's valuation to $2 billion. The biotech firm uses artificial intelligence to identify chemical compounds found in nature for new drug development, including current programs focused on treating skin conditions and maintaining weight loss following GLP-1 therapy.